Reshaping the HIV treatment and prevention landscape

Improved pipeline and productivity gsk Enabling growth for GSK over the next 10 years 2017-21 pipeline approvals account for >60% of expected 2021-26 sales CAGR Anticipated pipeline approvals account for >40% of expected 2021- 26 sales CAGR Pipeline delivery and business development - a continuing focus Stronger pipeline driven by a focus on the science of the immune system, human genetics and advanced technologies since 2017 - - - - - - 11 major new medicines and vaccines approved Top quartile performance vs peers in number of launches, R&D spend per launch, median PYS per launch >90% success rate for phase 3/pivotal studies Doubled the number of assets in pivotal studies or registration Around 20% reduction in overall cycle times across clinical development 50% increase in the average number of lifecycle projects per asset - - - PYS peak year sales 45

View entire presentation